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From the “Silent Killer” to the “Whispering Disease”:
Ovarian Cancer and the Uses of Metaphor
PATRICIA JASEN*
A Pulitzer Prize winning play by Margaret Edson, entitled W;t, begins with an
exchange between an oncologist, Dr Harvey Kelekian, and his patient, a John Donne
scholar and professor of English named Vivian Bearing. He is in the process of inform-
ing her that she has stage 4 ovarian cancer:
KELEKIAN: You have cancer ...you have advanced, metastatic ovarian cancer.
VIVIAN:G oo n...
KELEKIAN: You present with a growth that, unfortunately, went undetected in stages one, two and
three. Now it is an insidious adenocarcinoma, which has spread from the primary
adnexal mass—
VIVIAN: “Insidious”?
KELEKIAN: “Insidous” means undetectable at an—
VIVIAN: “Insidious” means treacherous.
KELEKIAN: Shall I continue?
VIVIAN: By all means.
Vivian then ponders what he has just said: “Insidious. Hmm. Curious choice of word.”
1
Edson’s opening scene focuses attention on the meanings of words which are used to
describe ovarian cancer. On the one hand, the physician understands himself to be using
the word “insidious” as it has become part of clinical language, to refer to a gradual,
undetectable and harmful physical process of the sort associated with ovarian cancer.
His patient, on the other hand, recognizes that the word is being used metaphorically.
As the Oxford English Dictionary defines it, “insidious” does mean “treacherous”, or
“full of wiles or plots, lying in wait to entrap or ensnare”, and is derived from the Latin
insidiae, meaning “ambush”, and insidiosus, meaning “cunning” or “deceitful”.
2
The purpose of this article is to examine the history and implications of ovarian
cancer’s association with metaphorical language. For most of the twentieth century,
the metaphor of the “silent killer”, often linked with the word “insidious”, was a com-
mon feature of ovarian cancer discourse, and this article explores the reasons why
that image became dominant and considers the role it played in both reflecting and
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489confirming established understandings of the disease. While the term “silent killer” has
sometimes been used to describe other cancers and is also applied to such illnesses
as hypertension and diabetes, its longstanding and very widespread use in defining
ovarian cancer is striking and deserves analysis, as does the process whereby its use
was challenged.
Some basic knowledge of the characteristics of ovarian cancer is useful when consi-
dering the language which has been used to describe the disease. While it is sometimes
still described as a rare disease, ovarian cancer affects as many as one in fifty-five
women in the United States.
3 It is now the second most commonly occurring gynaecolo-
gical cancer (after endometrial cancer) and, as a cause of cancer deaths in women, it
ranks fourth after lung, breast, and colorectal cancers.
4 There are many kinds of ovarian
cancer; as one recent text explains, the ovary “produces more varieties of tumors than
any other organ”.
5 Ovarian neoplasms are categorized according to three main types:
epithelial (accounting for over 90 per cent of malignant tumours); germ cell, which
includes the teratomas, as discussed in Jackie Stacey’s Teratologies: a cultural study
of cancer; and sex cord and stromal, which includes the granulosa cell tumour briefly
mentioned below.
6 The different kinds of ovarian cancer affect women at different stages
of life, with germ cell tumours most often occurring in women in their twenties and
thirties, while the median age for the diagnosis of epithelial carcinoma is around sixty.
7
Current medical literature discusses several possible aetiological factors, most of them
speculative, but authors tend to agree that continuous or “incessant” ovulation, uninter-
rupted by pregnancy or oral contraceptive use, has the strongest correlation with the
disease.
8 Like breast cancer, a portion of epithelial ovarian cancers (estimated at around
10 per cent) have a genetic link.
9 As yet, there is no accepted general screening test for
ovarian cancer, and diagnosis is often delayed due to a lack of specific symptoms or a
poor understanding on the part of patients or physicians of the signs of ovarian cancer.
When the disease is suspected, pelvic examination, sonography, and a blood test known
as CA-125 play a role in diagnosis.
10 Surgery confirms the presence of the disease and
the stage to which it has progressed. Ovarian cancer is staged according to whether it
is confined to the ovary (stage 1) or has extended beyond. In stage 2, the disease has
spread to the uterus, fallopian tube, or to other tissues in the pelvis; in stage 3, it has
metastasized to the abdominal cavity; and in stage 4, it has spread elsewhere in the
3Ivan K Strausz, You don’t need a hysterectomy:
new and effective ways of avoiding major surgery,
Cambridge, MA, Perseus, 2001, p. 302.
4Alexander F Burnett, Clinical obstetrics and
gynecology: a problem-based approach, Malden,
MA, and Oxford, Blackwell Science, 2001, p. 374.
5Ibid., p. 375.
6Kathleen M Brennan, Vicki V Baker
and Oliver Dorigo, ‘Premalignant and malignant
disorders of the ovaries and oviducts’, in Alan
J DeCherney, Lauren Nathan, T Murphy Goodwin
and Neri Laufer (eds), Current diagnosis and
treatment: obstetrics and gynecology, New York,
McGraw-Hill, 2007, pp. 872–77; Jackie Stacey,
Teratologies: a cultural study of cancer, London,
Routledge, 1997.
7Brennan, et al., op. cit., note 6 above, p. 875;
Tamara L Callahan, Aaron B Caughey, and Linda
J Heffner, Blueprints: obstetrics and gynecology,
Malden, MA, Blackwell, 2003, p. 258.
8Katherine Y Look, ‘Epidemiology, etiology, and
screening of ovarian cancer’, in Stephen C Rubin and
Gregory P Sutton (eds), Ovarian cancer,
Philadelphia, Lippincott, Williams and Wilkins, 2001,
pp. 168–74; Burnett, op. cit., note 4 above, p. 374;
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11 A recent text reports that, when diagnosed at stage 1, the five-year survival rate
for epithelial ovarian cancer is as high as 93 per cent, but, in over 70 per cent of patients,
the cancer has spread outside the pelvis by the time of diagnosis.
12 Aggressive surgery
and chemotherapy are employed to halt the disease, but at stage 3, the five-year survival
rate is 23 to 41 per cent, while at stage 4 it is only 5 to 11 per cent.
13 For much of the
past century, the deadly nature of advanced ovarian cancer, combined with the appar-
ently intractable difficulties associated with timely diagnosis, gave rise to the metaphor
of “the silent killer”, which, in turn, helped to shape understandings of the disease.
The significance of metaphor in medical language is the subject of an ongoing debate
which often refers back to Susan Sontag’s Illness as metaphor. In this work, first pub-
lished in 1978, Sontag made her now famous case against the mystification of illness
through the use of metaphor.
14 More recent writers, including the ovarian cancer patient
and sociologist Jackie Stacey, have criticized Sontag’s methodology and her basic pre-
mise that metaphorical thinking and language can be avoided in medical discourse.
15
James F Childress suggests that, partly because illness very often is mysterious, medicine
needs “the vision provided by metaphors, analogies, and symbols”, but he agrees with
Sontag that metaphors are not just evocative figures of speech; they have the power to
shape our understanding. Far from being “merely ornamental or affective”, he writes,
metaphors “can be and often are cognitively significant”.
16 In Medicine as culture,
Deborah Lupton supports this view by pointing out that, in medical discourse, as in
many kinds of communication, metaphor is “an epistemological device, serving to con-
ceptualize the world, define notions of reality and construct subjectivity”.
17
Other writers have shown that medical metaphors are deeply embedded in historical
contexts. Emily Martin points out that the dominant metaphor in early scientific medi-
cine was “the metaphor of the body as machine and the doctor as mechanic”.
18 With
the rise of bacteriology, metaphors of invasion and battle became commonplace, as
“bacteria were identified as agents of disease that threaten the body and its defenses”.
19
During the twentieth century, military metaphors came to dominate medical language,
and this was especially true in relation to cancer, as governments, especially in the
US, declared a “war on cancer” in the wake of the First World War.
20 Barron Lerner
has shown that the American Society for the Control of Cancer chose to use military
metaphors for very specific reasons, partly because they suited the mood of the inter-war
11Burnett, op. cit., note 4 above, p. 379.
12Brennan, et al., op. cit., note 6 above, pp. 883,
880.
13Ibid., p. 883.
14Susan Sontag, Illness as metaphor, New York,
Farrar, Straus and Giroux, 1978.
15Stacey, op. cit., note 6 above, pp. 44–8; Barbara
Clow, ‘Who’s afraid of Susan Sontag? Or, the myths
and metaphors of cancer reconsidered’, Soc. Hist.
Med., 2001, 14: 293–312.
16James F Childress, Practical reasoning in
bioethics, Bloomington, Indiana University Press,
1997, p. 4.
17Deborah Lupton, Medicine as culture, London,
Sage, 2003, p. 59.
18Emily Martin, The woman in the body:
a cultural analysis of reproduction, Boston, Beacon
Press, 2001, pp. 54–7.
19Childress, op. cit., note 16 above, p. 6.
20On inter-war cancer awareness campaigns in
the US, see Kirsten E Gardner, Early detection:
women, cancer, and awareness campaigns in the
twentieth-century United States, Chapel Hill,
University of North Carolina Press, 2006, pp. 17–92.
On the later response in Great Britain, see Elizabeth
Toon, ‘“Cancer as the general population knows it”:
knowledge, fear, and lay education in 1950s Britain’,
Bull. Hist. Med., 2007, 81: 116–38.
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491years, but also because they harnessed public fears and the willingness to fight a disease
which, by its very name, suggested an entity (the crab) “growing out of control and eat-
ing away at the body’s organs”.
21 Decades later, Sontag was highly critical of the way
that cancer continued to be personified as an “evil, invincible predator”, and maintained
that metaphors of invasion, battle, and defeat contribute to the stigma endured by cancer
patients.
22 But others have emphasized that military metaphors have positive uses, not
only in motivating social groups to fight disease but in supporting patients’ private strug-
gles to recover.
23 More recently, patients’ movements have explored alternatives to the
military metaphor, such as the image of cancer “as a journey”, while some practitioners
have wondered, more generally, whether a greater openness to new metaphors might
play a part in the re-conceptualization of medical problems.
24
Metaphors do not come into common usage unless, on some level, they work.
Throughout much of the twentieth century, both medical professionals and laypeople
applied military metaphors to cancer because they seemed both apt and useful. Cancer
was, as it is now, a disease the public feared above most others. Anti-cancer campaigns
focused on detecting the enemy early; patients and physicians fought diseases such as
breast and uterine cancer with all the heroic methods at their disposal; and survivors
celebrated their victories over the adversary. How did ovarian cancer fit into this picture?
As a less common form of cancer, it posed less of a public threat than breast or uterine
cancers and therefore attracted far less attention. It was also harder to detect, as it was
often without symptoms in its early stages, or was characterized by non-specific gastro-
intestinal complaints rather than typical warning signs such as a lump or irregular
bleeding. As a result, it had usually spread throughout the abdomen by the time it was
diagnosed and therefore had a very poor prognosis. For all of these reasons, it was a
poor target in the “war” on cancer, which depended upon an optimistic message to pro-
mote the promise of early detection and effective treatment.
25 Ovarian cancer was not
exempt from military metaphors, but the medical profession portrayed it as an enemy
which kills silently, progressing undetected until its victory is secure. Lack of success
in the search for early detection strategies allowed the image of the “silent killer” to
remain the dominant metaphor until the end of the twentieth century. By that point, how-
ever, an alternative metaphor was gaining ground, as ovarian cancer activists, convinced
that earlier detection was possible with closer attention to early symptoms, promoted the
image of a disease that “whispers” and can be “heard” if one knows what to listen for.
The “silent killer” metaphor was challenged because, in the view of some patients and
practitioners, it had become inaccurate and dangerously misleading. A growing body of
21Barron H Lerner, The breast cancer wars: fear,
hope, and the pursuit of a cure in twentieth-century
America, New York, Oxford University Press, 2001,
pp. 44–5. On public fear of cancer, see James
T Patterson, The dread disease: cancer and modern
American culture, Cambridge, Harvard University
Press, 1987.
22Sontag, op. cit., note 14 above, p. 7.
23Devra Davis, The secret history of the war on
cancer, New York, Basic Books, 2007, p. 16;
Childress, op. cit., note 16 above, p. 6.
24Childress, op. cit., note 16 above, p. 6; George
J Annas, ‘Reframing the debate on health care reform
by replacing our metaphors’, New Engl. J. Med.,
1995, 332: 744–47.
25Gardner makes only one reference to ovarian
cancer in Early detection, op. cit., note 20 above,
p. 209. She posits that “one reason that activists may
have directed little attention to ovarian cancer is that
early detection rhetoric had little resonance for this
cancer”.
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492medical evidence supported the hypothesis that an awareness of “early” symptoms might
hasten diagnosis and, with improvements in treatment, timely diagnosis became a major
factor in long-term survival. In June 2007, the American Cancer Society publicly disas-
sociated itself from the term “silent killer”—“a catchy phrase, but it is wrong”,
announced the ACS website.
26 The ACS and other agencies identified a list of common
symptoms which might be present even in early stage cancer, including bloating, fre-
quent urination, pain, and eating or digestive problems. These non-specific symptoms
had, in fact, been noted for decades, but new guidelines confirmed that if they were
new, persistent, and worsening, women should see a gynaecologist. Further tests would
then determine whether the risk involved in laparoscopic surgery was justified.
Before examining the uses of metaphor in relation to ovarian cancer in the twentieth cen-
tury, this article takes a brief look at how the disease was envisioned in the nineteenth
century in order to provide some historical context. It then analyses the reasons why the
“silent killer” metaphor became so prominent during the inter-war years, discusses some
of the means by which physicians attempted to control the disease, and notes that, by
mid-century, a small number of researchers were already questioning whether earlier atten-
tion tosymptomsmight haveaneffecton ovarian cancerdiagnosis. The“silentkiller” meta-
phor persisted, however, and, during the post-war decades, researchers focused on efforts to
improve treatment and, somewhat belatedly, the identification of risk factors such as family
history.Theyalsosearchedforatechnologicalsolutiontotheproblemofearlydetectionbut,
by the end of the century, it was clear that no viable means of mass screening had emerged.
The final section of the article traces the efforts of increasingly vocal patients and those
physicians and researchers who questioned the “silence” of ovarian cancer.
“Uncertain Sounds”:
Interpreting Ovarian Growths in the Nineteenth Century
Ovarian cancer, while a relatively rare condition compared with breast or uterine
cancers, was certainly not unknown to nineteenth-century physicians. They considered
it to be an invariably fatal disease, but found it was often impossible to distinguish
from non-cancerous growths unless it was very advanced. While the suspicion of breast
or uterine cancer was commonly aroused by the presence of a breast lump or unexplained
bleeding, the vague symptoms of ovarian cancer were usually recognized in retrospect
and were only occasionally mentioned in medical literature. The British surgeon Thomas
Spencer Wells, for example, looked back on the case history of one patient whose
tumour had caused “incontinence of urine” for three years before her admission to the
Samaritan Hospital, where she soon died.
27 The non-specific symptoms of the disease
were also noted by the cancer expert Walter Hayle Walshe, who remarked that the
patient might first report sensations that were “merely uneasy”, and that she might direct
26‘Ovarian cancer has early symptoms’, ACS
News Center, 14 June 2007, http://www.cancer.org/
docroot/NWS/content/NWS 1 x Ovarian Cancer
Symptoms The Silence Is Broken.asp (accessed
14/6/2009).
27T Spencer Wells, Diseases of the ovaries: their
diagnosis and treatment, New York, D Appleton,
1873, pp. 59–60.
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493attention to the ovary itself as the source of early pain.
28 The gynaecologist Charles Reed
concurred that the “symptomatology of ovarian neoplasms is sometimes very obscure”,
but acknowledged that there might be “a vague sense of discomfort in the pelvis”.
29
Even if symptoms had been noted more systematically in the nineteenth century,
earlier diagnosis would have been very unlikely to save women’s lives. Despite the
poor prognosis for ovarian cancer patients, ovarian growths of all sorts were of great
interest to nineteenth-century physicians. In good part, this was because the more com-
mon, non-cancerous cysts could become debilitating and even deadly if they grew large
enough, and there was good reason to seek new means of treatment.
30 Early in the cen-
tury, ovarian growths were treated by a wide variety of techniques, including drugs,
bleeding, purging, “blistering, electricity, friction, and abdominal pressure”, and by tap-
ping, or the removal of fluid.
31 The first successful ovariotomy (the term then used for
removal of the ovaries) was performed in 1809 by the Kentucky surgeon Ephraim
McDowell, who removed a 22
1/2 pound ovarian cyst. Other surgeons attempted similar
operations, and the first ovariotomy in Britain was performed in 1824.
32
The dangers involved in abdominal surgery, however, brought the procedure into dis-
repute. Not only was there a very high death rate, estimated at close to 50 per cent at
mid-century, but surgeries were performed on women who turned out not to have ovarian
disease at all or had cancerous tumours adhering to other abdominal structures, which
made effective surgery impossible.
33 Such a horrific procedure was not even recom-
mended for women who were thought to have ovarian cancer and were expected to die
anyway. In his Outlines of the principal diseases of females, Fleetwood Churchill
declared in 1838 that surgery was “never advisable, for at the advanced period, at which
alone so formidable an operation would be justifiable, the patient’s whole constitution is
contaminated by the cancerous diathesis”.
34 Many also questioned whether any woman
who might survive for some years without surgery should be exposed to such pain and
danger. Wells would eventually make his reputation as a leading ovariotomist, but he
recalled that in the early days “Surgeons stood and trembled on the brink of ovarian
waters.... Could we know beforehand that the circumstances would admit of such treat-
ment? The difficulty was in the diagnosis. There was a thick surgical darkness over the
abdomen, and it gave out only uncertain sounds.”
35
Although surgery was in disfavour at mid-century, within a few years the ovariotomy
would become an established, if still controversial, procedure.
36 The growing use of
anaesthetics increased the demand for and the acceptability of surgery, and, by the
28Walter Hayle Walshe, The nature and treatment
of cancer, London, Taylor and Walton, 1846,
pp. 344–5.
29Charles A L Reed, A text-book of gynecology,
New York, Appleton, 1901, p. 632.
30Ann Dally, Women under the knife: a history of
surgery, New York, Routledge, 1992, pp. 13–15.
31Ibid., p. 135.
32Ibid., 15–19, 135. On McDowell’s pioneering
surgery, also see Deborah Kuhn McGregor, From
midwives to medicine: the birth of American
gynecology, New Brunswick, NJ, Rutgers University
Press, 1998, p. 160.
33Ornella Moscucci, The science of woman:
gynaecology and gender in England, 1800–1929,
Cambridge University Press, 1990, p. 137.
34Fleetwood Churchill, Outlines of the principal
diseases of females, Dublin, Martin Keene and Son,
1838, p. 391.
35Wells, op. cit., note 27 above, p. 117.
36Moscucci, op. cit., note 33 above, pp. 156–60;
Lawrence D Longo, ‘The rise and fall of Battey’s
operation: a fashion in surgery’, Bull. Hist. Med.,
1979, 53: 244–57.
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4941870s, the introduction of antisepsis (or the new emphasis on general surgical cleanli-
ness, in the case of Listerism’s opponents), reduced the risk of infection and death. Wells
worked to perfect his technique by performing hundreds of ovariotomies at charity
hospitals such as the Samaritan Hospital for Women during the 1860s and 1870s,
and he claimed to have reduced the fatality rate in his cases from 50 per cent to
11 per cent.
37 Other prominent surgeons, including James Young Simpson and Robert
Lawson Tait, also became advocates, and ovariotomy, says Ann Dally, became “the
operation by which a surgeon’s skill and worth were assessed”.
38
Rising confidence in the safety of surgery, combined with a growing awareness of the
changeability of ovarian growths, caused some physicians to believe that the develop-
ment of life-threateningly large and even cancerous ovarian growths might be prevented
if surgery was undertaken sooner rather than later—that the risk of delay might outweigh
the risk of surgery. Benign tumours were increasingly recognized as being very prone to
cancerous changes; Wells’s extensive experience led him to observe that all ovarian
cysts had the potential to degenerate into “the worst forms of epithelial cancer”.
39 This
warning grew louder by the end of the century and became the primary argument for
immediate surgical intervention. In his textbook of gynaecology, Charles Reed, president
of the American Medical Association, advised that all growths needed to be investigated
because of the risk of “malignant degeneration”.
40
But the call for immediate action should not be taken to mean that surgeons expected
to save the lives of women in whom malignant ovarian growths had already developed.
As one London surgeon explained, it was more a matter that one should not assume a
tumour to be cancerous and therefore hopeless when surgery might prove that the diag-
nosis was mistaken.
41 Ovarian cancer was still regarded as “absolutely fatal”, for, as
another advised, even when the tumour is completely removed and “no metastases can
be discovered, a rapid return appears to be the invariable rule”.
42 In contrast with breast
cancer, for which radical surgery was being promoted as a potential cure, the fatal nature
of ovarian cancer drew frequent and despairing comment in turn-of-the-century medical
texts.
43
The “Silent Menace” and Early-Twentieth-Century Gynaecology
Throughout the early decades of the twentieth century, the fatalism surrounding ovar-
ian cancer stood in contrast to the rhetoric of optimism applied to some of the more com-
mon cancers in women. Cancer awareness campaigns, which emphasized the promise of
early detection, portrayed both breast and uterine cancers as enemies which could be
conquered through due vigilance on the part of patients and their physicians. Ovarian
37Moscucci, op. cit., note 33 above, pp. 152–6.
38Dally, op. cit., note 30 above, p. 139.
39Wells, op. cit., note 27 above, p. 58.
40Reed, op. cit., note 29 above, p. 633.
41George Ernest Herman, Diseases of women:
a clinical guide to their diagnosis and treatment,
London, Cassell, 1913, p. 746.
42R Olshausen, Diseases of the ovaries, ed.
Egbert H Grandin, New York, William Wood, 1887,
p. 384.
43Charles B Penrose, A text-book of diseases of
women, Philadelphia, W B Saunders, 1904,
pp. 392–3.
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495cancer, on the other hand, was increasingly envisaged as a “silent killer” which would
secure its deadly victory before it was even discovered.
One factor which may have enhanced the image of ovarian cancer as a particularly
deceptive disease was the growing fascination with the hormone-producing granulosa
cell tumour, even though it was a much less common form of the disease.
44 For research-
ers, especially those in the new field of endocrinology, this was an intriguing example of
pathological hormonal change. These oestrogen-producing tumours, only some of which
were cancerous, could cause early puberty and menstruation when they occurred in chil-
dren, but much more often they affected post-menopausal women who might briefly and
unwittingly welcome their “feminizing” effects.
45 “At the beginning”, wrote gynaecolo-
gists Emil Novak and J N Brawner in 1934, “there are only symptoms of hyperestrogen-
ism and the patient appears surprisingly and pleasantly to bloom again. However, this
cruel deception is not kept up for long, the disease soon destroying both this tragic illu-
sion and the body itself.”
46 The novelist Thomas Mann was so fascinated by this expres-
sion of “the cruel demonic side of nature” that he wrote a novella, entitled The black
swan, about a woman who dies from ovarian cancer after rejoicing in the return of her
youth. He sought to create, he said, “A story of deception, of a deadly hoax played by
Nature on its own good child.”
47
In the inter-war period and beyond, medical literature increasingly framed ovarian
cancer of all types as a cruel trick of nature, a disease which grew stealthily until it
was too late. The adjective “insidious” came into use; “Carcinoma of the ovary is the
most insidious disease of the generative tract” explained one text in 1927.
48 The
renowned gynaecologist Harry Sturgeon Crossen vividly evoked the “silent killer” meta-
phor when he reminded colleagues of the “symptomless onset and symptomless
progress” of this “creeping death which defies early discovery”.
49 Despite the relatively
low incidence of the disease, he and others pointed out that it was a greater threat than
some might think. Crossen suggested that one could “get some idea of the magnitude
and importance of this ‘silent menace’” by considering the many cases which each and
every gynaecologist had encountered in recent years, and by also adding the many other
patients, vaguely diagnosed with “abdominal” cancer, who might also have been victims
of ovarian malignancies.
50 By mid-century, it was not unusual for medical texts to refer
44John G Gruhn, ‘A selective historical survey of
ovarian pathology emphasizing neoplasm’, in
Lawrence M Roth and Bernard Czernobilsky (eds),
Tumors and tumorlike conditions of the ovary,
New York, Churchill Livingstone, 1985, pp. 269–85,
on p. 276.
45Fred L Adair (ed.), Obstetrics and gynecology,
2 vols, Philadelphia, Lea and Febiger, 1940, vol. 2,
p. 324.
46E Novak and J N Brawner, ‘Granulosa cell
tumors of ovary: clinical and pathological study of
36 cases’, Am. J. Obstet. Gynecol., 1934, 28: 637–49,
p. 637, quoted in Johannes Dietl, ‘Thomas Mann’s
last novella “The black swan”: the tragic story of a
post-menopausal woman’, Eur. J. Obstet. Gynecol.
Reprod. Biol., 2004, 113: 255–7, http://www.
sciencedirect.com (accessed 2/6/2009). Another view
is that Mann was writing about a victim of uterine
cancer; see Karen Nolte,‘Carcinoma uteri and
“sexual debauchery”—morality, cancer and gender in
the nineteenth century’, Soc. Hist. Med., 2008, 21:
31–46. Dietl’s interpretation seems most apt,
however, as the protagonist not only resumed her
menstrual period but “bloomed” again.
47Dietl, op. cit., note 46 above.
48Brooke M Anspach, Gynecology, Philadelphia,
Lippincott, 1927, p. 395.
49H S Crossen, ‘The menace of “silent” ovarian
cancer’, JAMA, 1942, 119: 1485–9, pp. 1486–7.
50Ibid., p. 1489.
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496to ovarian cancer as a “relatively common” disease, but not one which offered much
hope of a cure.
51
In spite of their general pessimism about treating ovarian cancer and the still very real
dangers of surgery, many surgeons during the inter-war years continued to advise an
aggressive approach to dealing with all ovarian masses in the hope of reducing the risk
of cancerous changes developing in benign cysts. Although there was a great variation
in opinion regarding the percentage of growths which would prove to be malignant, there
was a growing consensus by the 1930s that all were potentially deadly and that all must
be investigated as soon as they were detected.
52 “The division into malignant and non-
malignant tumors is important from the clinical aspect”, advised an Introduction to gyne-
cology, “but as a matter of fact practically all ovarian tumors possess potentialities for
malignant change.”
53 A very few gynaecologists even toyed with the hope that the lives
of at least some patients with ovarian cancer could be saved through timely surgery,
though reported rates of long-term survival remained extremely low.
54
Because ovarian cancer was so difficult to detect and treat, some surgeons advocated
prophylactic oophorectomy as a means of reducing the risk of ovarian cancer in post-
menopausal women. The removal of healthy ovaries was still a controversial procedure
and, as the frequency of hysterectomy increased during the early twentieth century, the
practice of performing oophorectomy at the same time caused divisions within the med-
ical profession. Crossen advocated the removal of the ovaries when abdominal surgery
was done for any reason in women past their childbearing years, which he set at forty-
two. He cited several cases from his own experience of women for whom he had per-
formed hysterectomies who later developed ovarian cancer. The lesson he had learned,
he confessed, was that he should never have left the ovaries intact: “I thought then
that it was advisable”, he wrote, “but I know better now.” He went on to explain that
although the ovaries “have a halo about them” they are of only temporary value. By
the time a woman is in her early forties, he wrote, they are “no longer an important
part of the economy but vestigal structures which carry a special tendency toward
cancer—and toward a particularly dangerous form of cancer, in that it develops to an
incurable stage without warning symptoms”.
55 Some other practitioners opposed the
procedure because the sudden hormonal change could render “the patient a physical
and nervous wreck”, which they saw as an unjustifiable outcome given the odds against
a malignancy ever developing.
56 Admitting that ovarian cancer was “a wholly unsolved
problem”, Clyde Randall of the University of Buffalo weighed the pros and cons of the
51Archibald Donald Campbell and Mabel
A Shannon, Gynecology for nurses, Philadelphia,
F A Davis, 1946, p. 144; Stanley Way, Malignant
disease of the female genital tract, London, J and
A Churchill, 1951, p. 182.
52Estimates ranged from 15 per cent in Arthur
Hale Curtis, A textbook of gynecology, Philadelphia,
W B Saunders, 1946, p. 391; to 25 per cent in Aleck
W Bourne and Leslie H Williams, Recent advances in
obstetrics and gynecology, Philadelphia, Blakiston,
1945, p. 290; to 35 per cent in Campbell and
Shannon, op. cit., note 51 above, p. 144.
53C Jeff Miller, An introduction to gynaecology,
St Louis, C V Mosby, 1934, p. 274.
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497procedure and concluded that perhaps “the all too apparent futility of our present treat-
ment may have cowed us to illogical extremes”.
57
As a second front in the struggle for ovarian cancer control, some gynaecologists also
advocated increased surveillance of middle-aged patients through regular pelvic exami-
nations. The growing acceptance of this procedure as a normal part of health care was
a side effect of the campaign to control uterine cancer, which encouraged apparently
healthy women to seek regular checkups. Crossen was adamant that examinations for
“silent” ovarian cancer should occur every six months, and there were a few gynaecolo-
gists who attempted to follow his lead. They noted, however, that the procedure, includ-
ing a rectal examination, must be conducted by physicians with considerable expertise,
and they acknowledged that this level of surveillance was impossible to establish and
maintain in entire populations.
58
Thus, as concern over ovarian cancer grew, emphasis was placed upon preventive sur-
gery and on signs which could be detected by the physician, rather than on sensations
which might be reported by the patient. The “silent killer” image was now firmly asso-
ciated with the disease, and some standard textbooks said nothing at all about its symp-
toms at any stage, thus leaving medical students and practitioners without a basis for
recognizing possible signs of ovarian cancer experienced by their patients. Other texts
mentioned only the symptoms of very advanced disease, while stressing that ovarian
tumours were “silent” until they were large and incurable.
59 Because most patients pre-
sented with pronounced swelling or pain prior to diagnosis, many physicians concluded
that those must, in fact, be the first symptoms, even though “careful questioning” might
reveal that the patient had experienced more subtle discomforts for a much longer period
of time.
60 These were the non-specific sensations of “unease”, along with urinary and
gastro-intestinal complaints, which had been remarked upon in nineteenth-century texts.
Physicians occasionally noted such complaints retrospectively; Crossen, for example,
chose twelve of his case histories to illustrate the “symptomless progress” of ovarian
cancer, including that of “Mrs. M.”, of whom he observed that, prior to her diagnosis,
she had no symptoms at all—merely “constipation for the past year and considerable
bloating”.
61
Given its neglect in medical literature, it not surprising that ovarian cancer symptoma-
tology was seldom discussed in cancer awareness campaigns aimed at the wider public.
The rhetoric of early detection focused on breast and uterine cancers, which were dis-
eases with a high incidence, specific (though not necessarily “early”) symptoms, and,
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498it was claimed, a good prognosis if found soon enough.
62 Articles in women’s magazines
and advice manuals intended for the middle-aged woman confined themselves to identi-
fying breast lumps and several varieties of irregular bleeding as the danger signs which
must not be ignored.
63 For example, in a popular work entitled The woman asks the
doctor (1944), the leading American gynaecologist Emil Novak included an entire chap-
ter entitled ‘Cancer, The Arch-Enemy of Women’ which focused exclusively on breast
and uterine cancers and made no mention of ovarian cancer at all.
64
Even though the rhetoric of early detection seemed not to apply to ovarian cancer, an
interest in pursuing a more nuanced understanding of its non-specific symptoms did
emerge within a very small minority of medical researchers on both sides of the Atlantic.
Through retrospective studies, they began, as early as the 1930s, to take note of the wider
pattern of their patients’ complaints and to tabulate symptoms in order of frequency for
more systematic analysis.
65 Most importantly, they began to record the occurrence of
mild but persistent gastro-intestinal complaints and to consider their relevance in relation
to ovarian cancer detection. The British gynaecologist Beckwith Whitehouse paid a good
deal of attention to “the complex subject of symptomatology”, and in 1931 reported that,
in a series of 200 cases of ovarian disease, digestive symptoms “occurred in 29% of my
simple cases and 41% of the malignant”.
66 John Montgomery of the Jefferson Medical
College Hospital repeated the usual refrain about the silence of ovarian cancer, but
none the less reported that 37 per cent of his patients “had abdominal symptoms, mostly
referable to the gastrointestinal tract for six months to several years before a pelvic
examination was made. One patient, the sister of a physician, was given ‘samples’ for
‘indigestion’ for three years before her abdomen began to swell.”
67
At mid-century, another prominent British gynaecologist, Stanley Way, made a con-
certed effort to draw colleagues’ attention to this very issue. He did not deny that of
“all the aspects of ovarian cancer, the symptomatology is the least satisfactory”, but he
proposed that abdominal discomfort and persistent digestive problems were likely the
earliest symptoms of the disease in a great many cases. Relying, as had others, on case
histories of cancer patients to illustrate the problem, he recounted the death of a
52-year-old woman who succumbed shortly after exploratory surgery was performed.
Two years before she died, “[S]he had been investigated in a London teaching hospital
for vague abdominal pain thought to be due to pyelitis, and six months after this she
had again been investigated in the medical department of a large provincial hospital
for ‘indigestion’ thought to be due to a gastric ulcer.” He insisted that because “vague
62Gardner, op. cit., note 20 above, pp. 8, 30–8.
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499digestive disturbances” were so common in ovarian cancer patients they must be consid-
ered to be “of diagnostic importance”. Lamenting that the number of ovarian cancers
which “have been nurtured in a sea of bicarbonate of soda and potassium citrate by
the practitioners of the world” was beyond calculation, he insisted that all women over
forty who complained of such symptoms should be fully examined.
68
Old Metaphors and New Strategies
Way’s advice seems to have had little impact, and few researchers in the post-war
decades challenged the image of the “silent killer”. The illness attracted growing atten-
tion, however, partly because its incidence appeared to be on the rise. In 1954, one
gynaecologist reported a “startling increase of 40 per cent” in the ovarian cancer death
rate in New York State over the previous twenty years, and researchers in both North
America and Great Britain reported upward trends over the following decades.
69 The
risk of developing the disease, reported to be 1 in 100 in 1965, had risen to 1 in 70 by
the 1980s and was reported to be as high as 1 in 55 by the mid-1990s, although the rea-
sons underlying this apparent increase were obscure.
70 Rising incidence combined with
poor survival rates meant that it was a growing threat compared with other gynaecologi-
cal cancers. In 1979, one American researcher pointed out that “more women die as a
result of the ravages of this insidious ... neoplasm ... than succumb to cervical and
endometrial cancer combined”, and another reported in 1983 that “one woman dies
from ovarian cancer every 50 minutes in this country”.
71
In the face of such discouraging facts, researchers sought new means of gaining con-
trol over the disease. Important advances in surgery and chemotherapy were made, but
their long-term impact was limited by the fact that a majority of cases were not diag-
nosed until metastasis had occurred.
72 By the 1980s, more concerted attention was
finally given to the long-neglected epidemiology of ovarian cancer, and some progress
was made in identifying women at increased risk who might benefit from increased sur-
veillance.
73 Much effort was devoted, as well, to development of mass screening techni-
ques which might make earlier diagnosis possible for all patients, but results on that front
were disappointing.
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500The first risk factor to be systematically examined was low parity, although there was
much disagreement over why it might predispose women to ovarian cancer. The debate
centred on the question of whether “poor reproductive performance”, optional or other-
wise, was in itself a source of risk, or whether low parity was to be interpreted as a
sign of poor ovarian health which might lead to malignancy.
74 The New York ovarian
cancer expert Hugh Barber declared in 1978 that: “Women at high risk usually have a
long history of ovarian imbalance or dysfunction, including ... a tendency for sponta-
neous abortion, infertility, and nulliparity, as well as an early menopause. The ovary is
like a cam running off center.”
75 At the same time, other researchers emphasized that
the protection afforded by pregnancy was probably the key factor, because unmarried
and childless married women both had a higher incidence of the disease.
76 More studies
followed and yet the question remained open, complicated by the fact that the known
causes of infertility were so diverse.
77
Attention was also turned to another hypothesis, first put forward in 1971, that unin-
terrupted or “incessant” ovulation might be an important factor in the aetiology of ovar-
ian cancer.
78 This theory was compatible with studies suggesting that the contraceptive
pill, which prevented ovulation, had a very significant protective effect. The U.S. Center
for Disease Control, for example, estimated that “oral contraceptive use alone may have
prevented up to 1700 cases of ovarian cancer” in 1982.
79 Some years later, the theory
that frequent ovulation might predispose women to the disease provided an explanation
for an emerging association between ovarian cancer and the use of fertility drugs. As
women became more vocal about their right to know about potential risks associated
with drugs and medical treatments, some cancer patients would charge that fertility
clinics were negligent in not providing this information.
80
The question of a hereditary factor was also given serious consideration in 1980s.
Instances of individual families with a high incidence of the disease had been mentioned
in the late nineteenth century, and, from the 1930s onwards, studies of affected families
grew slowly in number. One such study, published in 1950 by Amour Fiscus Liber, con-
cerned ‘Ovarian cancer in mother and five daughters’. At the time, Liber was a lone
voice calling for radical action based on his assumption of a genetic link. Although, in
his words, he stopped short of advocating “eugenic limitation of breeding”, he recom-
mended prophylactic oophorectomy for women in families thus affected, close monitor-
ing from an early age, and the creation of agencies to keep records of all cases—even
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501suggesting that, if possible, autopsies be performed not only on patients but on all rela-
tives, including males, in case “there is a recognizable phenotype of male carriers”.
81
During the 1950s and 1960s, the importance of a genetic link was widely dismissed,
but by the 1970s the number of families on record was increasing rapidly, and there
was speculation that the incidence of familial disease was actually growing.
82 In 1981,
the first Familial Ovarian Cancer Registry in the US was established at Roswell Park
Memorial Institute in Buffalo. Its goal was not merely to study the “mode of inheritance”
but to examine relationships with breast and other cancers, as well as inter-connections
with other suspected risk factors, including asbestos exposure.
83 That same year, a
widely cited study reported that women with a mother or sister with the disease had an
alarming eighteen-fold increase in risk, and during the 1980s there was much speculation
upon the nature of the familial link, whether screening procedures should be introduced
for high-risk women, and whether prophylactic oophorectomy should be recom-
mended.
84 In the early 1990s, the BRCA1 and BRCA2 genes associated with both breast
and ovarian cancer were localized, removing all doubt that women in certain families
faced an extremely high level of hereditary risk.
85
Because the incidence of ovarian cancer was much higher in western industrialized
countries than elsewhere, researchers also investigated cultural and environmental fac-
tors. One of these was a possible association with asbestos exposure in the workplace
and the use of talc (contaminated by asbestos until at least the mid-1970s) in personal
hygiene. A 1960 study had suggested that women with asbestosis had a higher rate of
ovarian cancer, and another published in 1971 directed attention towards the possible
link with talc by reporting that, in the set of ovarian tumours which they examined,
75 per cent contained talc particles.
86 That study and others proposed that this factor
might actually help to account for the rising incidence of ovarian cancer in the post-
war decades.
87 Further investigations demonstrated that talc applied to the genital area
could make its way very rapidly into the peritoneal cavity, and a case control study pub-
lished in 1982 found that 42.8 per cent of the women with ovarian cancer had used
talc regularly, compared with 28.4 per cent of the controls.
88 The association between
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502asbestos exposure, talc use and ovarian cancer remained controversial, however, because
researchers continued to produce conflicting results.
89
In addition to the examination of potential risk factors, a second approach to the
growing incidence of ovarian cancer was the search for a means of effectively screen-
ing asymptomatic women—either entire populations, or only those deemed to be high
risk. By the mid-1980s, three main screening techniques were available; these were the
manual pelvic examination, the ultrasound technology which had been developed dur-
ing the previous decades, and the recently devised CA-125 blood test, which measured
the level of a cancer antigen associated with ovarian cancer.
90 As already mentioned,
many physicians viewed regular pelvic examinations as an important means of detect-
ing potential cancers in asymptomatic women, but others increasingly opposed this
strategy, arguing that pelvic examination was limited in sensitivity and did not yield
“the desired percentage of early diagnoses”. Ovarian cancer was found in only about
one in 10,000 such procedures, while, at the same time, about one examination in
125 revealed some sort of mass which, they pointed out, resulted in unnecessary anxi-
ety and potentially hazardous surgery.
91 Ultrasound technology, meanwhile, held out
the hope that masses not felt during examination could be detected through imaging,
a n da l s ot h a tm a n u a l l yl o c a t i n gam a s sw o u l db e“ s a f e r ”i fi tc o u l dt h e nb ea s s e s s e d
without surgery.
92 Ultrasound offered a step forward but was found to be too inaccu-
rate, and too costly, for general screening, while the CA-125 blood test was neither
specific nor sensitive enough for regular use in asymptomatic women (though both
came into use for monitoring women considered high risk).
93 Despite efforts to
d e v e l o pa ne a r l yd e t e c t i o np r o g r a m m ew h i c hp a r a l l e l e dm a m m o g r a p h ya n dt h eP a p
smear, no viable strategy emerged for ovarian cancer.
94
Meanwhile, during the second half of the twentieth century, medical literature of
various kinds re-confirmed the image of the “silent killer”. “Ovarian cancer, is unfor-
tunately, very insidious and ‘silent’ in terms of signs and symptoms”, reiterated
Novak’s authoritative text in 1988, and similar language appeared in many other
works.
95 But, as the prospect of mass screening for ovarian cancer proved elusive,
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503some voices were raised in favour of giving more attention to the non-specific symp-
toms which women could detect themselves, and of questioning the very use of the
term “silent killer”. “Evidence that current screening techniques reduce mortality is
lacking”, wrote one team. “Therefore, symptom recognition is important in the detec-
tion of ovarian cancer.”
96 Due to “problems with sensitivity and specificity”, decided
another, “we have to rely on the woman and her initiative in order to achieve an early
diagnosis.”
97
From the “Silent Killer” to the “Whispering Disease”
Increasing attention to ovarian cancer symptoms coincided with a much wider
women’s health movement in the 1980s and 1990s. Its objectives were many, but a cen-
tral goal was to transform the clinical encounter through the legitimization of patients’
own experiences of health and illness. For the nascent ovarian cancer movement,
much of the focus was on reducing the risk of wrong or delayed diagnosis through edu-
cating both physicians and the public about the common symptoms of “the disease that
whispers”. This campaign would eventually lead to collaboration between patient acti-
vists and members of the research community and, by the early twenty-first century, to
official recognition of a pattern of what would now be termed “early” symptoms, accom-
panied by a widening critique of the “silent killer” metaphor.
A start was made in 1978 when Hugh Barber revived Stanley Way’s plea of nearly
three decades before, declaring it was time “to change the generally accepted notion
that there are no early symptoms” of ovarian cancer. Like Way, Barber observed
that women’s complaints of increased girth and gastro-intestinal problems were rou-
tinely dismissed or wrongly diagnosed. “Allt o oo f t e n ” ,h ew r o t e ,“ t h ep a t i e n ti sc o n -
sidered a middle-aged crock who goes to too many cocktail parties and eats too many
hors d’oeuvres.”
98 A year later, the South Dakota physician Brooks Ranney used
patients’ records to tabulate the symptoms they had experienced and confirmed that
most patients, including women with stage 1 and 2 disease, who therefore had a
much better prognosis, had noticed symptoms over a period of two weeks to ten
years.
99 In 1985, an Iowa team collected information from patients rather than
from clinical records, and found that “[i]n sharp contrast to clinical perceptions and
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504previous research ...three fourths of women with locally staged tumors of the ovary”
had symptoms ranging from swelling to fatigue, pain, problems with urination, indi-
gestion, irregular bleeding, shortness of breath, and bowel changes. Nearly half of
the women had dismissed these discomforts as “not serious”, especially those under
forty and over fifty. They concluded that localized cancer did have symptoms, and
that helping women to recognize them was an important public health priority.
100 Phy-
sicians, as well, needed to know what they were, and a Swedish team pointed out that,
“[h]owever vague the symptoms, there are some that should alert the clinician to the
possibility of ovarian cancer”.
101
That call was repeated at intervals during the 1990s. Researchers continued to observe
the long delays that separated the onset of symptoms from correct diagnosis and the chal-
lenge of finding a doctor “who is familiar with the symptoms of ovarian cancer”.
102
Their efforts attracted less attention than they might have hoped, and physicians’ uneven
knowledge of the disease was the subject of a pair of studies conducted in 1999. The first
surveyed primary care physicians and achieved a response rate of just over one half.
Within this group, the researchers reported a good deal of variation in respondents’ abil-
ity to identify risk factors correctly, while the accurate identification of symptoms ranged
from 60 per cent for weight gain to 94 per cent for ascites (abdominal fluid).
103 An odd
feature of this first study was that the authors’ list of six symptoms omitted any reference
to the common signs of indigestion, bloating, and changes in bowel habits. The second
study, however, which measured gynaecologists’ perceptions, did include abdominal
bloating and altered bowel function (but excluded indigestion), and a strong majority
of respondents recognized these symptoms. Only 62 per cent identified the use of fertility
drugs as a potential risk factor, however, and 71 per cent identified a previous history of
breast cancer.
104
The contrast between physicians’ sometimes limited knowledge and their seemingly
unlimited authority was of major importance to women’s health activists in the 1980s
and 1990s. This growing movement questioned the assumption that lay knowledge was
necessarily inferior to biomedical knowledge and protested the dismissal of women’s
intimate experience of their bodies. Activists sought to recover “the voice of the subject”
and to recognize the role of intuition in relation to health and illness, despite the difficul-
ties inherent in defining that concept.
105 These concerns would have particular resonance
for the ovarian cancer movement, which—while hampered by the fact that many potential
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505activists did not survive many years after treatment began—was intensely motivated by
the need to improve the possibility of earlier diagnosis.
Like many other aspects of the women’s health movement, ovarian cancer activism
was strongly influenced by what Laura Potts described in her study of breast cancer nar-
ratives as “a dominant culture of revelation, disclosure, and the making of testimony”.
106
The disease story is an old genre, but during the late twentieth century it became a
powerful means of giving voice to the personal experience of cancer and of furthering
the goals of the women’s health movement.
107 This sense of purpose was shared by
writers of ovarian cancer narratives and, as was the case with breast cancer, the process
began with the publication of testimonies written by well-known women such as the
NBC correspondent Betty Rollin (who wrote about her mother’s illness and death from
ovarian cancer), the comedian and actress Gilda Radner, Cosmopolitan editor Barbara
Creaturo, and Liz Tilberis, editor-in-chief of Harper’s Bazaar.
108
Radner revealed that she unknowingly had most of the risk factors for ovarian cancer,
including a strong family history and the use of fertility drugs. She did not recognize her
own symptoms (“my stomach felt bloated and hard”), was diagnosed with stomach pro-
blems by her gynaecologist and gastroenterologist, and spent months seeking an explana-
tion for her increasing painful condition before finally being told she had ovarian cancer,
stage 4. Her physician and family friend Steven Piver recalled that, at the time of her
death in the spring of 1989, he assumed that the publicity surrounding her ordeal would
mean that “the days of no newspaper or magazine articles or television specials on ovar-
ian cancer were over”.
109 Radner’s death was certainly a turning point, with both Piver
and her husband, Gene Wilder, taking up the cause of early detection, but the struggle
for public awareness would continue.
Many women who were not in the public eye were also motivated to publicize their
experiences, whether in books, newspaper articles, or online. By the turn of the century,
ovarian cancer patients by the hundreds were telling their stories on the internet where,
as for many diseases, websites were being created which provided ordinary people
with a forum for sharing their perspectives on the experience of cancer. On these sites,
entries could be very brief and still serve some of the same purposes as other cancer nar-
ratives. As Shani Orgad writes in Storytelling online, the process of writing “allows the
author to make sense of her experience; to organize people, events, and information that
she encountered, into a coherent framework of meaning”.
110 Using such narratives as
historical sources obviously has limitations; as Potts says, disease stories tend to have
“an aura of authenticity” when in reality they are one person’s version of events, possibly
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506related in a time of crisis.
111 As a means of entry into that experience of crisis, however,
they are a valuable resource.
Ovarian cancer narratives are both similar to and different from most other types of
cancer stories. A shared feature is the motif of “the enterprising self”, as Orgad calls
it, through which the patient is cast as the protagonist embarking on a challenging jour-
ney.
112 In ovarian cancer narratives, however, the theme of “the enterprising self” often
emerges most powerfully during the quest for a diagnosis, when the obstacle to be over-
come, through courage and persistence, is not yet the disease itself but medical profes-
sionals who do not recognize the symptoms of ovarian cancer or seem unwilling to
listen to patients’ complaints. All such accounts are necessarily retrospective; they
look back, after a diagnosis has been made, to the symptoms which preceded it and
the false starts which were made in identifying the disease.
In writing such narratives, some patients recalled that they were not aware that ovar-
ian cancer was called the “silent killer” until after their disease was recognized, but
they later identified the term as a factor in their delayed or incorrect diagnoses. One
such story was that of Ayala Miron, the editor of a book titled Ovarian cancer jour-
neys. She was diagnosed in 2000 after several years of reporting symptoms to her doc-
tors and two trips to the emergency ward, where she was diagnosed with a gallbladder
attack on the first visit and diverticulitis on the second.
113 “As it turned out”, wrote
Miron,
my health care providers had completely misdiagnosed my symptoms. They didn’t know enough
about ovarian cancer and did not suspect that my complaints were serious. After my ovarian cancer
diagnosis, I realized that this disease caused the symptoms I felt. I also learned that many health
care providers mistakenly consider ovarian cancer “a silent disease”. My symptoms, over a number
of years, taught me differently.
114
Miron attributed health care professionals’ apparent lack of awareness to the influence
of the “silent disease” image but also suggested that she, herself, failed to identify the
symptoms she was experiencing because she was uninformed.
The Johns Hopkins Pathology Ovarian Cancer Website provided a forum for women
to write about their personal experiences with ovarian cancer in the early twenty-first
century, and it became a particularly rich source of patient perceptions regarding the
process of diagnosis. Stories of long delay were legion, and a repeated theme was
that both physicians and patients must be made aware of the symptoms which may sig-
nal ovarian cancer. For example, Amy Chaiklin described “the laparoscopic discovery
of ovarian cancer after 13 years of suffering”, while Becky Bennett recalled experienc-
ing swelling and discomfort in the early 1990s, noticed a “lop-sided” abdominal enlar-
gement by 1994, began to have problems with urination in 1999, and was diagnosed
with a ten-pound tumour in 2001.
115 A woman signing herself as “Barbara”, in a tes-
timony reminiscent of Stanley Way’s warning fifty years earlier, wrote of “popping
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507Tum’s [sic] and over-the-counter gas medications like crazy” and being diagnosed
with acid reflux, while “Chris Y.” wrote of being told for three years that she had
endometriosis and was then treated for a kidney infection before her diagnosis.
116
Donna McNulty related that her swollen stomach was attributed to peri-menopausal
weight gain; her bloating and nausea were treated as acid reflux; and her constant
need to urinate was diagnosed as a bladder infection—all common occurrences in
women, but symptoms which, seen together, comprise a pattern typical of ovarian can-
cer.
117 Judy Lidgate experienced the usual symptoms and was told she was suffering
from depression, while Karen Leonard’s intense pain was attributed to gallstones or
a parasite.
118 An especially common misdiagnosis was irritable bowel syndrome, or
IBS, and women sometimes blamed themselves for not questioning their diagnosis.
Augusta Gluck admitted, “I regret that I accepted the diagnosis of irritable bowel syn-
drome and did not investigate further ...But I had seen my internist, my gynecologist,
and a gastroenterologist. No one even mentioned that my symptoms might have been
ovarian cancer and my life threatened by it.”
119
Often employing the term “whispering disease” brought into use by the ovarian cancer
movement, such testimonies addressed the relationship between the two principal meta-
phors considered in this paper. They argued that ovarian cancer is not “silent” but that
women must “listen” to their bodies in order to recognize the signs of “the disease that
whispers”. They urged others to put aside their fears of disapproval, trust their own per-
ceptions and intuitions, and—shifting their use of the word “listen” to its more literal
sense—demand their doctors’ attention: “Don’t just listen to your body (we all know
or have heard that ovarian cancer whispers), make sure the doctor is listening, too.”
120
The notion of “the disease that whispers” itself came under criticism, however, for it
lacked resonance for women whose symptoms had become intense well before they
were diagnosed. As one woman declared in a newspaper interview, “It’s such a whimpy,
cop-out term. I hate it. It’s not a whispering disease. It’s a shouting disease.”
121 Another
woman, a long-term survivor of stage 4 cancer, told of how by the time a diagnosis was
reached “the ‘disease that whispers’ was screaming out to her”.
122 The majority, none the
less, focused on the need to heed the earlier, subtler symptoms of ovarian cancer, and
various permutations of “the whispering disease” metaphor gained wide currency in
the ovarian cancer movement.
123
In spite of the efforts of the ovarian cancer movement, many women’s health manuals
and menopause guidebooks, written by women’s health advocates and physicians, were
slow to reflect need for more information about symptoms of the disease. In part, this
reticence may have reflected other priorities of the women’s health movement. The
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508prophylactic removal of healthy ovaries when hysterectomies were performed was still
common, and one way to counter that practice was to downplay the danger of ovarian
cancer. Lonnie Barbach’s The pause, for example, assured readers that ovarian cancer
is a sufficiently rare disease that the ovaries “should not be removed preventatively”.
124
Even in the early twenty-first century, most health manuals aimed at middle-aged women
said little or nothing about ovarian cancer symptoms. In her Menopause and hormone
book, Dr Susan Love passed lightly over the complexities of ovarian cancer diagnosis
with the simple comment that there is “no good way to detect it early”, while Ivan K
Strausz’s You don’t need a hysterectomy described the early symptoms of the disease
as “entirely inconspicuous” and remained highly pessimistic about the prospect of timely
diagnosis.
125 And yet, this neglect was far from uniform, for the Boston Women’s Health
Book Collective had already begun, as early as the 1984 edition of Our bodies ourselves,
to detail the “warning signs” of ovarian cancer which, they cautioned, “are frequently
dismissed merely as ‘stress’ or nerves’”. These symptoms included “indigestion, gas,
constipation or diarrhea, loss of appetite or weight, a feeling of fullness, lower abdominal
discomfort or pain, frequent urination, fatigue, backache, nausea, vomiting, nonmenstr-
ual vaginal bleeding, enlargement or bloating of the abdomen or an unusual growth or
lump”. Persistence of such symptoms, they advised, called for “a thorough physical eva-
luation for ovarian cancer” by means of a symptom review, family history, pelvic and
rectal examination, CA-125 blood test, and ultrasound.
126 This disparity within the pop-
ular women’s health literature shows that information about symptoms and diagnostic
procedures was available to the public, even if many authors chose not to include it in
their works.
“Official” Recognition of Ovarian Cancer Symptoms
By the late 1990s, a growing body of research was providing more and more evi-
dence that there was, indeed, a pattern of early warning signs of ovarian cancer which
should be more widely publicized and acted upon. The growing ovarian cancer move-
ment, meanwhile, lobbied for further research initiatives, and, on occasion, worked
with members of the research community to document ovarian cancer symptom pat-
terns. One leading activist was Cindy Melancon, a registered nurse living in Amarillo,
T e x a s ,w h ow a sd i a g n o s e di n1 9 9 2a n ds t a r t e dan e w s l e t t e r ,Conversations,a sa
forum for women with ovarian cancer and as a vehicle for disseminating informa-
tion.
127 A seminal moment in the relationship between lay activists and professional
researchers came in 1998, when Barbara Goff, a gynaecologic oncologist from Seattle,
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509Washington, met Melancon at a conference for the lay public. As Goff described the
meeting:
Cindy and other survivors challenged the notion that ovarian cancer is a silent disease. After listen-
ing to these survivors’ exceptional stories, I decided to team up with Cindy so that we could eval-
uate symptoms and early diagnosis in a scientific manner. During medical school, residency, and
even gynecologic oncology fellowship I had been taught that ovarian cancer was a silent disease
and so initially I was not optimistic that our studies would yield new information.
128
Although a number of researchers were already challenging the language long used to
describe ovarian cancer, the findings of Goff and her colleagues would eventually prove
to be a turning point. Their first study was published in the American Cancer Society’s
journal Cancer in 2000. It was a retrospective study based on information collected from
ovarian cancer patients through a survey sent to subscribers of Melancon’s newsletter,
and the authors concluded that the great majority of women diagnosed at an early stage
experienced symptoms. They analysed the reasons for delays in detecting the disease,
ranging from women’s own ignorance of symptoms to dismissive attitudes on the part
of some physicians and the failure to perform pelvic examinations or order tests. While
acknowledging the possibility of both selection bias (the women were Melancon’s sub-
scribers) and recall bias (they were recalling symptoms after receiving their diagnoses),
Goff’s team concluded that “women with ovarian carcinoma do have symptoms in con-
trast to what is stated in most textbooks and taught in most medical schools”.
129 A sec-
ond study responded to the problem of bias and also addressed a concern voiced by
primary care physicians, which was that the non-specific symptoms of ovarian cancer
are experienced by a great many women and can hardly be considered a guide to early
diagnosis. By tabulating symptoms experienced during the past year by women about
to undergo surgery for a pelvic mass compared with two control groups attending
primary care clinics, the team found that, while women commonly reported at least
one of the symptoms associated with ovarian cancer, those eventually diagnosed with
the disease had much more severe, frequent and varied symptoms, even compared
with women suffering from IBS. They concluded that their study “adds further evidence
that ovarian cancer is not a silent disease”.
130
Otherresearchers pursued the same question, and their combined workeventuallyled toa
public statement released in June 2007 by the American Cancer Society, the Gynecologic
Cancer Foundation, and the Society of Gynecologic Oncologists announcing that, for the
first time, a “national consensus” had been reached in the US regarding early signs of ovar-
ian cancer.
131 The signs were listed as “bloating, pelvic or abdominal pain, trouble eating or
feeling full quickly” and “urinary symptoms, such as urgent or frequent feelings of needing
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132 The news media quickly spread the word, and Goff was one of the main spokes-
people called upon to interpret these findings to the public. “There’s been this myth about
ovarian cancer being silent and people saying there’s nothing you can do about it”, Fox
News reported her as saying, “well, that’s simply not true anymore.”
133 In an interview
with Jim Lehrer on PBS, the American public television network, Goff addressed the old
problem of the non-specificity of symptoms by explaining that “it’s not simply just having
the symptom that is important”, but that the symptom is new, persistent, and increases in
severity.
134 “The majority of time”, she advised, such symptoms will not signify ovarian
cancer, “but it’s justsomethingthatshould beconsidered.”
135She recommendedthatpersis-
tent symptoms, when reported by patients, should lead to a pelvic examination, including “a
recto-vaginalexamsothatthe ovariescanbeappropriatelyfelt”, followedbyultrasound and
a CA-125 blood test, if warranted. If the ultrasound detected a mass and the blood test
revealed an elevation of a tumour marker that is common with ovarian cancer, the patient
should be referred to a specialist in gynaecologic cancers.
136 Debbie Saslow, director of
breast and gynaecologic cancer at the American Cancer Society, was also widely quoted,
and spoke to the still relevant concern over causing more women to undergo unnecessary
and hazardous surgery. She revealed that the ACS still had reservations about the recom-
mendations, due to the fact that “[w]e don’t have any consensus about what doctors should
do once the women come to them”.
137 None the less, leading members of the cancer
research community stood firmly behind the public statement. Columbia University’s direc-
torofgynaecologiconcology,ThomasJHerzog,commented,that“Bynomeansdowewant
this toresultinunnecessarysurgery.But I would not expectthattooccur inthe vastmajority
of cases.” He also saw a need for physicians to reverse their old approach and discuss the
existence of early symptoms with their patients so that women might become “more pro-
active” in recognizing them. The gynaecologic oncologist Carol Brown, at Manhattan’s
Memorial Sloan Kettering Cancer Center, agreed that “[t]his is something that women
themselves can do”.
138 While the June 2007 announcement did not suddenly produce a
consensus within the medical community regarding the significance of early symptoms,




This article has examined ovarian cancer’s long association with the metaphor of the
“the silent killer” and has traced the process by which that metaphor, and the understand-
ing of ovarian cancer symptoms which it signified, were eventually challenged in the
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511pages of medical journals and through the voices of ovarian cancer activists. It has
attempted to show that, while the use of metaphorical language in medical discourse is
inevitable, metaphors arise within particular contexts and may outlive their utility in
expressing medical realities. In the early twentieth century, within the context of the
“war” on cancer, the adoption of the “silent killer” metaphor in medical texts reflected
the fact that the disease almost always progressed to an advanced stage before it was
diagnosed and was almost always fatal. These factors also supported its exclusion
from public information campaigns and popular medical literature aimed at women read-
ers. From mid-century onwards, a small number of physicians openly questioned the
accuracy of this metaphor and the medical assumptions which it signified, but only dur-
ing recent years were the existence of early symptoms and their possible role in diagnosis
widely and publicly addressed in both the lay and medical press. The association of the
“silent killer” metaphor with ovarian cancer was exceptionally tenacious, and it arguably
played a role in diverting attention away from systematic attention to symptoms which
were later deemed relevant by a growing number of researchers. This history provides
support for the conclusion that medical metaphors do have a role in defining “notions
of reality” and therefore deserve close scrutiny.
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